The outcome of a randomised phase II trial evaluating olaparib alone or in combination with atezolizumab (NCT02849496) in metastatic homologous recombination deficient HER-2 negative breast cancer will provide further data regarding the true synergy of PARPi and ICI in clinical terms in the metastatic setting. The gene discussed is ERBB2; the disease is breast cancer.